This position plays a critical role in the development and execution of BMS' WW & US medical strategy within our Mavacamten (Camzyos®) cardiovascular portfolio. The Global Medical Mavacamten Medical Product Lead (MPL) is a strategic leader with a broad scope of responsibilities within the Worldwide Medical organization and a key leader of the cross-functional matrix, providing medical insights and interpretation of the evolving cardiomyopathy landscape and disseminating clinical data across the organization. The MPL has overall accountability to develop aligned medical strategies and execute core medical deliverables, including Integrated Evidence Plans, Scientific Narratives, and External Engagement and Advocacy plans as the lead of the cross-functional Asset/Indication Medical Strategy (AIMS) team.

The Senior Director, MPL will have oversight over the Mavacamten asset across the full spectrum of hypertrophic cardiomyopathy (HCM) indications - both obstructive (oHCM) and non-obstructive (nHCM) - and related life cycle management opportunities, and should be able to direct and navigate complex issues across the broad cross-functional matrixed partners to ensure optimal medical affairs strategy is developed and executed.

• Develop and execute the WW & US Medical Affairs strategy for Mavacamten (Camzyos®) across all HCM indications, including obstructive and non-obstructive HCM, ensuring alignment with the overall BMS cardiovascular disease area strategy.
• Act as the core global medical representative for WW & US Mavacamten Program Teams, providing strategic medical and scientific leadership across all cross-functional forums.
• Lead the cross-functional Asset/Indication Medical Strategy (AIMS) team for Mavacamten, setting strategic direction and aligning medical deliverables across global markets.
• Ensure Mavacamten is effectively positioned within the BMS cardiovascular disease area strategy, integrating competitive intelligence and an evolving understanding of the cardiomyopathy landscape.
• Participate in the Cardiovascular Leadership Team (LT) to drive business priorities and represent the medical affairs perspective at the highest organizational levels.
• Oversee and guide asset development strategy across the full Mavacamten life cycle, including new indications, label expansions, and post-marketing evidence generation in HCM and related cardiomyopathies.
• Develop and execute WW & US medical strategy, scientific narratives, and provide medical insights to inform the global medical plan for Mavacamten, with deep expertise in myosin inhibition and cardiac muscle physiology.
• Lead workstreams to identify evidence gaps and develop comprehensive Integrated Evidence Plans (IEPs), including both interventional and non-interventional research strategies in HCM populations globally.
• Establish and oversee global medical data generation strategies; collaborate with Medical Evidence Generation (MEG) to oversee the execution of Investigator Sponsored Research (ISR) programs for Mavacamten from concept through full execution, including reporting at scientific congresses, in peer-reviewed publications, and through proactive/reactive BMS communication tools.
• Deliver WW & US Medical Communications plans for Mavacamten, including global publications strategy, symposia, scientific exchange, and data dissemination at key cardiovascular congresses (e.g., AHA, ACC, ESC, HFSA).
• Engage with high-impact global external thought leaders and cardiovascular experts in HCM to identify and translate key insights, and drive adoption of Mavacamten/Camzyos® across global markets.
• Partner closely with colleagues in Discovery, Clinical Research, Regulatory, and Health Outcomes to ensure the science of Mavacamten and the broader cardiovascular pipeline is understood and communicated properly, both internally and externally.
• Contribute to shaping competitive strategies around pricing and reimbursement by providing the global medical perspective on the target product profile, label language, and value considerations for Mavacamten.
• Demonstrate the ability to make effective decisions on selecting external organizations and researchers with appropriate cardiovascular/HCM expertise for research collaborations globally.
• Shape and represent BMS' scientific leadership in cardiomyopathy at international scientific meetings, advisory boards, and with key global health authorities and cardiology societies.

Qualifications & Experience

• Life sciences and/or healthcare professional training with an advanced degree is required (MD, PharmD, PhD).
• Minimum of 8+ years working in the pharmaceutical industry (Medical Affairs/Medical Strategy, Clinical Research) with experience in cardiovascular medicine, preferably with direct experience in cardiomyopathy, heart failure, or related therapeutic areas.
• Deep scientific knowledge of hypertrophic cardiomyopathy (HCM) - including disease pathophysiology, treatment landscape, and the clinical evidence base for myosin inhibition - is preferred.
• The successful candidate should have strong analytical skills, strong scientific data and evidence interpretation + contextualization, and the ability to work effectively with cross-functional teams including clinical, commercialization, regulatory, HEOR and Access.
• Excellent strategy development, critical thinking, decision making, and demonstrated ability to successfully create and implement both short and long-range global medical plans.
• Proven track record of engaging global/international KOLs and cardiovascular thought leaders; demonstrated ability to build and sustain high-impact external scientific relationships.
• Experience leading global medical affairs programs and working effectively in a worldwide matrixed organization across multiple geographies and cultures.
• Entrepreneurial thinking, anticipates needs, assesses and manages business and organizational risks in a complex global environment.
• Highly organized and motivated and possesses excellent people management, interpersonal, and strong communication skills.
• Must be familiar with all phases of drug development, including clinical development, regulatory, and life cycle management in a global context.
• Launch expertise in cardiovascular therapeutic area, preferably with experience in rare cardiovascular disease or specialty cardiology.
• HQ based position with international/domestic travel requirement approximately 20-30%.

#LI-HYBRID

Compensation Overview:

Princeton - NJ - US: $229,380 - $277,956

The starting compensation range(s) for this role are listed above for a full-time employee (FTE) basis. Additional incentive cash and stock opportunities (based on eligibility) may be available. The starting pay rate takes into account characteristics of the job, such as required skills, where the job is performed, the employee's work schedule, job-related knowledge, and experience. Final, individual compensation will be decided based on demonstrated experience.

Eligibility for specific benefits listed on our careers site may vary based on the job and location. For more on benefits, please visit https://careers.bms.com/life-at-bms/.

Benefit offerings are subject to the terms and conditions of the applicable plans in effect at the time and may require enrollment. Our benefits include:

• Health Coverage: Medical, pharmacy, dental, and vision care.
• Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP).
• Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support.

Work-life benefits include:

Paid Time Off

• US Exempt Employees: flexible time off (unlimited, with manager approval, 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees)
• Phoenix, AZ, Puerto Rico and Rayzebio Exempt, Non-Exempt, Hourly Employees: 160 hours annual paid vacation for new hires with manager approval, 11 national holidays, and 3 optional holidays

Based on eligibility*, additional time off for employees may include unlimited paid sick time, up to 2 paid volunteer days per year, summer hours flexibility, leaves of absence for medical, personal, parental, caregiver, bereavement, and military needs and an annual Global Shutdown between Christmas and New Years Day.

All global employees full and part-time who are actively employed at and paid directly by BMS at the end of the calendar year are eligible to take advantage of the Global Shutdown.

*Eligibility Disclosure: The summer hours program is for United States (U.S.) office-based employees due to the unique nature of their work. Summer hours are generally not available for field sales and manufacturing operations and may also be limited for the capability centers. Employees in remote-by-design or lab-based roles may be eligible for summer hours, depending on the nature of their work, and should discuss eligibility with their manager. Employees covered under a collective bargaining agreement should consult that document to determine if they are eligible. Contractors, leased workers and other service providers are not eligible to participate in the program.